Vimpat and Calcinosis - a phase IV clinical study of FDA data

Summary:

Calcinosis is reported as a side effect among people who take Vimpat (lacosamide), especially for people who are female, 40-49 old, have been taking the drug for 1 - 2 years also take Keppra, and have Convulsion.

The phase IV clinical study analyzes which people have Calcinosis when taking Vimpat. It is created by eHealthMe based on reports of 20,279 people who have side effects when taking Vimpat from the FDA, and is updated regularly.

What is Vimpat?

Vimpat has active ingredients of lacosamide. It is often used in epilepsy. eHealthMe is studying from 20,831 Vimpat users. Check the latest studies of Vimpat.

What is Calcinosis?

Calcinosis (calcium deposits in any soft tissue) is found to be associated with 412 drugs and 859 conditions by eHealthMe. Check the latest studies of Calcinosis.

On Jul, 23, 2026

20,279 people reported to have side effects when taking Vimpat.
Among them, 22 people (0.11%) have Calcinosis.

Among these 22 people:

How long have people been on Vimpat when they have Calcinosis? *

What is the gender of people who have Calcinosis when taking Vimpat? *

female: 95.24 %
male: 4.76 %

What is the age of people who have Calcinosis when taking Vimpat? *

What are other drugs people take besides Vimpat? *

What are other side effects people have besides Calcinosis? *

Lymphangioleiomyomatosis (a rare lung condition that affects a certain type of muscle cell and only occurs in women): 19 people, 86.36%
Drug Resistance (reduction in effectiveness of a drug): 19 people, 86.36%
Drug Ineffective: 19 people, 86.36%
Angiomyolipoma (most common benign tumour of the kidney): 19 people, 86.36%
Angiofibroma (small, reddish brown or even flesh-coloured, smooth, shiny, 0.1- to 0.3 cm papules present over the sides of the nose and the medial portions of the cheeks): 19 people, 86.36%
Urinary Tract Infection: 1 person, 4.55%
Rib Fracture: 1 person, 4.55%
Pruritus Generalised (generalized itching): 1 person, 4.55%
Nasopharyngitis (inflammation of the nasopharynx): 1 person, 4.55%
Memory Loss: 1 person, 4.55%

What are the existing conditions these people have? *

Tuberous Sclerosis (a rare genetic disease that causes benign tumours to grow in the brain and other organs): 2 people, 9.09%
Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 2 people, 9.09%
Stress And Anxiety: 1 person, 4.55%
Paroxysmal Nocturnal Haemoglobinuria (haemoglobin in the urine): 1 person, 4.55%
Insomnia (sleeplessness): 1 person, 4.55%
Diarrhea: 1 person, 4.55%
Attention Deficit Hyperactivity Disorder (a chronic condition including attention difficulty, hyperactivity, and impulsiveness): 1 person, 4.55%

* Approximation only. Some reports may have incomplete information.

Do you take Vimpat and have Calcinosis?

- Check whether Calcinosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Vimpat:

Vimpat (20,831 reports)

Calcinosis treatments and more:

Calcinosis (3,651 reports)

Browse all side effects of Vimpat:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Calcinosis:

Calcinosis (412 drugs)

Browse all the conditions that are associated with Calcinosis:

Calcinosis (859 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on lacosamide (the active ingredients of Vimpat) and Vimpat (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.